Nucleus plus
  • Patient Care
  • About
 
 

05.03.22

Lenalidomide plus CD23.CAR T Cell Therapy in CLL

by ASTCT Science Highlights

Tettamanti S, Rotiroti MC, Arcangeli S, et al. Lenalidomide Enhances CD23.CAR T Cell Therapy in Chronic Lymphocytic Leukemia. Leukemia & Lymphoma. 2022; (doi: 10.1080/10428194.2022.2043299).

The tumor microenvironment (TME) observed in chronic lymphocytic leukemia (CLL) patients exhibits immunosuppressive behavior that affects the efficacy of chimeric antigen receptor (CAR) T-cells, but pairing the cells with lenalidomide may be a solution. Researchers engineered T cells from patients with CLL to express a CAR directed at the antigen CD23, which has demonstrated therapeutic potential in this patient population. While the CLL TME normally keeps CAR T cells from doing their job effectively, adding lenalidomide — an immunomodulatory agent — allowed CD23.CAR+ T cells to execute effector functions related to antigen-specific cytotoxicity, cytokine release, and proliferation. Lenalidomide maintained functional CAR T-CLL cell immune synapses. In a xenograft model of CLL, CD23.CAR+ T cells efficiently migrated to leukemic sites and slowed disease progression when delivered in tandem with lenalidomide versus with rhIL-2. The study authors believe their findings have positive implications for CAR-based treatment of CLL.

Read More

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
08.02.22
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
by ASTCT Science Highlights
Single-Cell Antigen-Specific Landscape of CAR T Infusion Product Identifies Determinants of CD19-Positive Relapse in Patients with ALL
07.28.22
Single-Cell Antigen-Specific Landscape of CAR T Infusion Product Identifies Determinants of CD19-Positive Relapse in Patients with ALL
by ASTCT Science Highlights
Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL
07.26.22
Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL
by ASTCT Science Highlights
footer divider

ASTCT

American Society for Transplantation
and Cellular Therapy

330 North Wabash Avenue, Suite 2000
Chicago, IL 60611, USA
Phone: (312) 321-6820
Fax: (312) 673-6733

facebook youtube twitter linkedin
Login
Search